Claims
- 1. A method of eliciting an immune response in a subject, comprising the steps of:
(a) providing a recombinant AAV vector containing a nucleic acid molecule encoding at least one antigen of interest operably linked to control sequences which direct the expression of said antigen of interest in a suitable recipient cell; and (b) introducing said recombinant AAV vector into a recipient cell of said subject under conditions that permit the expression of said one or more antigen, thereby eliciting an immune response to said antigen of interest.
- 2. The method of claim 1, wherein said immune response comprises production of cytotoxic T lymphocytes directed against said antigen of interest.
- 3. The method of claim 1, wherein said immune response comprises production of antibodies directed against said antigen of interest.
- 4. The method of claim 1, wherein said immune response comprises production of interleukin-2 and gamma interferon.
- 5. The method of claim 4, wherein said immune response is a TH1-like response.
- 6. The method of claim 1, wherein said immune response comprises the production of one or more cytokines selected from the group consisting of interleukin-4, interleukin-5, interleukin-10, and interleukin-13.
- 7. The method of claim 6, wherein said immune response is a TH2-like response.
- 8. The method of claim 1, wherein said antigen of interest comprises at least one antigen selected from the group consisting of tumor antigens, viral antigens, bacterial antigens, and protozoal antigens.
- 9. The method of claim 1, wherein said antigen of interest is derived from an intracellular pathogen.
- 10. The method of claim 1, wherein said antigen of interest is a self-antigen.
- 11. The method of claim 1, wherein said antigen of interest is an allergen.
- 12. The method of claim 1, wherein expression of said antigen of interest persists for approximately eight weeks after said introducing said antigen of interest to said recipient cell of said subject.
- 13. The method of claim 1, wherein expression of said antigen of interest persists for at least eight weeks after introducing said antigen of interest to said recipient cell of said subject.
- 14. The method of claim 1, wherein said recombinant AAV vector comprises a recombinant AAV virion.
- 15. A method for shifting the cytokine profile of an immune response against an antigen in a subject, comprising the steps of:
(a) providing a recombinant AAV vector containing a nucleic acid molecule encoding at least one antigen of interest operably linked to control sequences which direct the expression of said antigen of interest in a suitable recipient cell; and (b) introducing said recombinant AAV vector into a recipient cell of said subject under conditions that permit the expression of said antigen, thereby eliciting a desensitizing immune response specific for said antigen.
- 16. The method of claim 15, wherein said antigen is an allergen.
- 17. The method of claim 16, wherein said shifting in the immune response is characterized by a switch from a TH1-like response to a TH2-like response.
- 18. The method of claim 15, wherein said recombinant AAV vector comprises a recombinant AAV virion.
- 19. A method for treating or preventing an autoimmune disease in a vertebrate subject, said method comprising:
(a) providing a recombinant AAV vector containing a nucleic acid molecule encoding an antigen against which an immune response is mounted in the autoimmune disease, wherein said nucleic acid molecule is operably linked to control sequences which direct the expression thereof in a suitable recipient cell; and (b) introducing said AAV vector into a recipient cell of said vertebrate subject under conditions that permit the expression of said antigen in an amount sufficient to bring about a reduction in a cytotoxic immune response or a desensitizing immune response against said antigen.
- 20. The method of claim 19, wherein said recombinant AAV vector comprises a recombinant AAV virion.
- 21. A method for modulating allergic reaction in a vertebrate subject, said method comprising:
(a) providing an AAV vector containing a nucleic acid molecule encoding an immunogenic molecule having a first portion derived from an IgE molecule and a second portion derived from an immunogenic carrier molecule, wherein the nucleic acid molecule is operably linked to control sequences which direct the expression thereof in a suitable recipient cell; and (b) introducing said AAV vector into a recipient cell of said vertebrate subject under conditions that permit the expression of said immunogenic molecule, thereby eliciting an immune response against IgE molecules in the vertebrate subject.
- 22. The method of claim 21, wherein said recombinant AAV vector comprises a recombinant AAV virion.
- 23. An in vitro target system for monitoring an immune response to an antigen of interest in a vertebrate sample, said system comprising a population of target cells transduced with an AAV vector containing a nucleic acid molecule encoding the antigen of interest operably linked to control sequences which direct the expression thereof in the target cell, wherein said target cell is capable of presenting the antigen of interest associated with a MHC class I molecule.
Government Interests
[0001] This invention was funded in part by grants CA71725, HL57443, and CA72103 from the National Institutes of Health. The U.S. Government has certain rights in this invention. This application claims priority benefit of U.S. provisional application No. 60/053,733, filed Jul. 25, 1997, pending, which is hereby incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60053733 |
Jul 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09121162 |
Jul 1998 |
US |
Child |
09858728 |
May 2001 |
US |